U.S. Markets closed

Lixte Biotechnology Holdings, Inc. (LIXT)


Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.140.00 (0.00%)
At close: 1:41PM EDT
People also watch
ARNIIRSBISLTGOVXOVIT

Lixte Biotechnology Holdings, Inc.

248 Route 25A, No. 2
East Setauket, NY 11733
United States
631-942-7959
http://www.lixte.com

Sector
Industry
Full Time Employees

Key Executives

NameTitlePayExercisedAge
Dr. John S. Kovach M.D.Founder, Chairman, Chief Exec. Officer, Pres, CFO and Principal Accounting Officer60kN/A80
Mr. Gil N. Schwartzberg Esq.ConsultantN/AN/AN/A
Dr. Francis Johnson Ph.D.ConsultantN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company’s primary focus is to develop various treatments for human cancers and other non-malignant diseases, including vascular diseases, such as heart attacks and strokes, and diabetes, as well as genetic diseases comprising Gaucher’s disease; and depression and post-traumatic stress syndrome. It develops protein phosphatase inhibitors that include LB-100 series of compounds; and histone deacetylase inhibitors, which comprises LB-200 series of compounds for the treatment of cancer, as well as in the prevention and treatment of neurodegenerative diseases, which are under various stages of pre-clinical and clinical developments. The company was founded in 2005 and is based in East Setauket, New York.

Corporate Governance

Lixte Biotechnology Holdings, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.